Compare CORT & FRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | FRHC |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.3B |
| IPO Year | 2001 | 1996 |
| Metric | CORT | FRHC |
|---|---|---|
| Price | $114.03 | $173.41 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $141.00 | N/A |
| AVG Volume (30 Days) | ★ 815.6K | 49.0K |
| Earning Date | 11-03-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.29 |
| EPS | 0.09 | ★ 0.52 |
| Revenue | $761,407,000.00 | ★ $2,191,291,000.00 |
| Revenue This Year | $50.53 | N/A |
| Revenue Next Year | $48.75 | N/A |
| P/E Ratio | $1,275.83 | ★ $329.96 |
| Revenue Growth | ★ 12.79 | 6.86 |
| 52 Week Low | $28.66 | $107.98 |
| 52 Week High | $126.38 | $178.00 |
| Indicator | CORT | FRHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 52.02 |
| Support Level | $108.33 | $145.61 |
| Resistance Level | $124.30 | $174.21 |
| Average True Range (ATR) | 5.17 | 4.91 |
| MACD | -0.14 | -0.39 |
| Stochastic Oscillator | 53.19 | 43.05 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Freedom Holding Corp is a holding company with reportable segments into the following four segments: Brokerage, Banking, Insurance, and Other. The majority of revenue is from the Banking segment. Banking segment consists of the operations of Freedom Bank KZ and Freedom Bank TJ. Geographically, operates in Kazakhstan, Armenia, Cyprus, the USA, and others, with maximum revenue from Kazakhstan.